TipRanks
Guardant Health (MX:GH)
:GH
Mexico Market
GH
Guardant Health
RESEARCH TOOLSreports

Guardant Health (GH) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

GH Analyst Ratings

Strong Buy
20Ratings
Strong Buy
20 Buy
0 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Guardant
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GH Stock 12 Month Forecast

Average Price Target

$3,784.11
▲(35.92% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $3,784.11 with a high forecast of $4,174.78 and a low forecast of $3,339.83. The average price target represents a 35.92% change from the last price of $2,784.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"954":"$954","4175":"$4,175","1759.25":"$1,759.3","2564.5":"$2,564.5","3369.75":"$3,369.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4174.7843025,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3784.1069566611104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.78K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3339.827442,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.34K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[954,1759.25,2564.5,3369.75,4175],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2784,2890.983407884615,2997.966815769231,3104.950223653846,3211.9336315384617,3318.917039423077,3425.9004473076925,3532.8838551923077,3639.8672630769233,3746.8506709615385,3853.8340788461537,3960.8174867307694,4067.800894615385,{"y":4174.7843025,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2784,2860.931304358547,2937.8626087170937,3014.793913075641,3091.725217434188,3168.6565217927346,3245.5878261512817,3322.5191305098288,3399.450434868376,3476.3817392269225,3553.3130435854696,3630.244347944016,3707.1756523025633,{"y":3784.1069566611104,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2784,2826.755957076923,2869.511914153846,2912.2678712307693,2955.0238283076924,2997.7797853846155,3040.5357424615386,3083.291699538461,3126.0476566153843,3168.8036136923074,3211.5595707692305,3254.3155278461536,3297.0714849230767,{"y":3339.827442,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":955.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1810,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1810,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2590,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2784,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2784,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2784,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$4,175Average Price Target$3,784Lowest Price Target$3,340
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on MX:GH
Mark Massaro
BTIG
BTIG
$3,618.15→$3,896.47
Buy
39.96%
Upside
Reiterated
10/27/26
Guardant Health price target raised to $210 from $195 at BTIGGuardant Health price target raised to $210 from $195 at BTIG
Roth MKM Analyst forecast on MX:GH
Max Masucci
Roth MKM
Roth MKM
$3,710.92
Buy
33.29%
Upside
Initiated
10/22/26
Guardant Health initiated with a Buy at Roth CapitalGuardant Health initiated with a Buy at Roth Capital
Morgan Stanley Analyst forecast on MX:GH
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$3,710.92
Buy
33.29%
Upside
Reiterated
10/20/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Alvotech (NASDAQ: ALVO)
Bernstein Analyst forecast on MX:GH
Eve Burstein
Bernstein
Bernstein
$3,896.47
Buy
39.96%
Upside
Assigned
10/19/26
Bernstein Remains a Buy on Guardant Health (GH)
J.P. Morgan Analyst forecast on MX:GH
Casey Woodring
J.P. Morgan
J.P. Morgan
$3,618.15
Buy
29.96%
Upside
Reiterated
10/14/26
Analysts' Top Healthcare Picks: Agilent (A), Guardant Health (GH)
Bank of America Securities Analyst forecast on MX:GH
Lu Li
Bank of America Securities
Bank of America Securities
$3,618.15→$3,710.92
Buy
33.29%
Upside
Reiterated
10/09/26
Guardant Health price target raised to $200 from $195 at BofAGuardant Health price target raised to $200 from $195 at BofA
Barclays Analyst forecast on MX:GH
Luke Sergott
Barclays
Barclays
$3,710.92→$4,082.01
Buy
46.62%
Upside
Reiterated
10/07/26
Barclays Sticks to Its Buy Rating for Guardant Health (GH)
Guggenheim Analyst forecast on MX:GH
Subbu Nambi
Guggenheim
Guggenheim
$3,525.37→$3,710.92
Buy
33.29%
Upside
Reiterated
10/01/26
Guardant Health price target raised to $200 from $190 at GuggenheimGuardant Health price target raised to $200 from $190 at Guggenheim
Goldman Sachs Analyst forecast on MX:GH
Evie Koslosky
Goldman Sachs
Goldman Sachs
$3,896.47→$4,174.78
Buy
49.96%
Upside
Reiterated
09/20/26
Guardant Health (GH) Gets a Buy from Goldman Sachs
Craig-Hallum Analyst forecast on MX:GH
William Bonello
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
09/15/26
Analysts Are Bullish on These Healthcare Stocks: NeurAxis, Inc. (NRXS), Guardant Health (GH)
Piper Sandler Analyst forecast on MX:GH
David Westenberg
Piper Sandler
Piper Sandler
$3,581.04
Buy
28.63%
Upside
Reiterated
09/15/26
Piper Sandler Sticks to Their Buy Rating for Guardant Health (GH)
UBS Analyst forecast on MX:GH
Doug Schenkel
UBS
UBS
$3,247.05→$4,174.78
Buy
49.96%
Upside
Reiterated
09/09/26
Guardant Health assumed with a Buy at UBSGuardant Health assumed with a Buy at UBS
William Blair Analyst forecast on MX:GH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Guardant Health: FDA Companion Dx Approval for Camizestrant Validates Longitudinal Liquid Biopsy and Supports Buy Rating
Rothschild & Co Redburn Analyst forecast on MX:GH
Jamie Clark
Rothschild & Co Redburn
Rothschild & Co Redburn
$3,766.58
Buy
35.29%
Upside
Initiated
09/08/26
Guardant Health initiated with a Buy at Rothschild & Co RedburnGuardant Health initiated with a Buy at Rothschild & Co Redburn
Mizuho Securities Analyst forecast on MX:GH
Bradley Bowers
Mizuho Securities
Mizuho Securities
$3,710.92
Buy
33.29%
Upside
Reiterated
08/04/26
Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on MX:GH
Mark Massaro
BTIG
BTIG
$3,618.15→$3,896.47
Buy
39.96%
Upside
Reiterated
10/27/26
Guardant Health price target raised to $210 from $195 at BTIGGuardant Health price target raised to $210 from $195 at BTIG
Roth MKM Analyst forecast on MX:GH
Max Masucci
Roth MKM
Roth MKM
$3,710.92
Buy
33.29%
Upside
Initiated
10/22/26
Guardant Health initiated with a Buy at Roth CapitalGuardant Health initiated with a Buy at Roth Capital
Morgan Stanley Analyst forecast on MX:GH
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$3,710.92
Buy
33.29%
Upside
Reiterated
10/20/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Alvotech (NASDAQ: ALVO)
Bernstein Analyst forecast on MX:GH
Eve Burstein
Bernstein
Bernstein
$3,896.47
Buy
39.96%
Upside
Assigned
10/19/26
Bernstein Remains a Buy on Guardant Health (GH)
J.P. Morgan Analyst forecast on MX:GH
Casey Woodring
J.P. Morgan
J.P. Morgan
$3,618.15
Buy
29.96%
Upside
Reiterated
10/14/26
Analysts' Top Healthcare Picks: Agilent (A), Guardant Health (GH)
Bank of America Securities Analyst forecast on MX:GH
Lu Li
Bank of America Securities
Bank of America Securities
$3,618.15→$3,710.92
Buy
33.29%
Upside
Reiterated
10/09/26
Guardant Health price target raised to $200 from $195 at BofAGuardant Health price target raised to $200 from $195 at BofA
Barclays Analyst forecast on MX:GH
Luke Sergott
Barclays
Barclays
$3,710.92→$4,082.01
Buy
46.62%
Upside
Reiterated
10/07/26
Barclays Sticks to Its Buy Rating for Guardant Health (GH)
Guggenheim Analyst forecast on MX:GH
Subbu Nambi
Guggenheim
Guggenheim
$3,525.37→$3,710.92
Buy
33.29%
Upside
Reiterated
10/01/26
Guardant Health price target raised to $200 from $190 at GuggenheimGuardant Health price target raised to $200 from $190 at Guggenheim
Goldman Sachs Analyst forecast on MX:GH
Evie Koslosky
Goldman Sachs
Goldman Sachs
$3,896.47→$4,174.78
Buy
49.96%
Upside
Reiterated
09/20/26
Guardant Health (GH) Gets a Buy from Goldman Sachs
Craig-Hallum Analyst forecast on MX:GH
William Bonello
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
09/15/26
Analysts Are Bullish on These Healthcare Stocks: NeurAxis, Inc. (NRXS), Guardant Health (GH)
Piper Sandler Analyst forecast on MX:GH
David Westenberg
Piper Sandler
Piper Sandler
$3,581.04
Buy
28.63%
Upside
Reiterated
09/15/26
Piper Sandler Sticks to Their Buy Rating for Guardant Health (GH)
UBS Analyst forecast on MX:GH
Doug Schenkel
UBS
UBS
$3,247.05→$4,174.78
Buy
49.96%
Upside
Reiterated
09/09/26
Guardant Health assumed with a Buy at UBSGuardant Health assumed with a Buy at UBS
William Blair Analyst forecast on MX:GH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Guardant Health: FDA Companion Dx Approval for Camizestrant Validates Longitudinal Liquid Biopsy and Supports Buy Rating
Rothschild & Co Redburn Analyst forecast on MX:GH
Jamie Clark
Rothschild & Co Redburn
Rothschild & Co Redburn
$3,766.58
Buy
35.29%
Upside
Initiated
09/08/26
Guardant Health initiated with a Buy at Rothschild & Co RedburnGuardant Health initiated with a Buy at Rothschild & Co Redburn
Mizuho Securities Analyst forecast on MX:GH
Bradley Bowers
Mizuho Securities
Mizuho Securities
$3,710.92
Buy
33.29%
Upside
Reiterated
08/04/26
Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
SIBNSI-Bone
AORTArtivion
PHVSPharvaris
HELPHelus Pharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

3 Months
Luke SergottBarclays
Success Rate
12/17 ratings generated profit
71%
Average Return
+27.52%
Copying Luke Sergott's trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +27.52% per trade.
1 Year
Daniel BrennanTD Cowen
Success Rate
17/18 ratings generated profit
94%
Average Return
+109.38%
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +109.38% per trade.
2 Years
Daniel BrennanTD Cowen
Success Rate
18/18 ratings generated profit
100%
Average Return
+245.23%
Copying Daniel Brennan's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +245.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GH Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
7
1
0
0
0
Buy
40
64
50
53
32
Hold
2
1
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
49
66
50
54
33
In the current month, GH has received 32 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. GH average Analyst price target in the past 3 months is 3,784.11.
Each month's total comprises the sum of three months' worth of ratings.

GH Financial Forecast

GH Earnings Forecast

Next quarter’s earnings estimate for GH is -$14.00 with a range of -$16.80 to -$11.94. The previous quarter’s EPS was -$16.80. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s earnings estimate for GH is -$14.00 with a range of -$16.80 to -$11.94. The previous quarter’s EPS was -$16.80. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Sales Forecast

Next quarter’s sales forecast for GH is $6.55B with a range of $6.39B to $6.70B. The previous quarter’s sales results were $6.25B. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s sales forecast for GH is $6.55B with a range of $6.39B to $6.70B. The previous quarter’s sales results were $6.25B. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Stock Forecast FAQ

What is MX:GH’s average 12-month price target, according to analysts?
Based on analyst ratings, Guardant Health’s 12-month average price target is 3,784.11.
    What is MX:GH’s upside potential, based on the analysts’ average price target?
    Guardant Health has 35.92% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Guardant Health a Buy, Sell or Hold?
          Guardant Health has a consensus rating of Strong Buy, which is based on 20 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Guardant Health’s share price target?
            The average share price target for Guardant Health is 3,784.11. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $4,174.78 ,and the lowest forecast is $3,339.83. The average share price target represents 35.92% Increase from the current price of $2,784.
              What do analysts say about Guardant Health?
              Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of Guardant Health?
                To buy shares of MX:GH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.